Abbott Mixes Bunts with Homerun Swings in Drug Research

Drugmakers get dinged all the time for working on “me-too” medicines that offer only incremental benefits over drugs already on the market. Abbott Labs’ head of pharma R&D, John Leonard, is unapologetic. He told the Health Blog during a recent interview that it’s only prudent to include low-risk projects in a company’s research pipeline. A [...]